Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 8/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6258542 | 0.81 | DRD2 (0.68) | ATMDRD2DRD4OPRM1DRD3 | |
| SCHEMBL5857455 | 0.79 | ATM (0.57) | ATMDRD2DRD4OPRM1DRD3 | |
| SCHEMBL10668664 | 0.78 | KIF11 (0.42) | ATMDRD2DRD4OPRM1DRD3 | |
| SCHEMBL28141509 | 0.77 | TAAR1 (0.46) | ATMDRD2DRD4OPRM1DRD3 | |
| SCHEMBL3979738 | 0.77 | CYP2D6 (0.58) | ATMDRD2DRD4OPRM1DRD3 | |
| SCHEMBL11712752 | 0.77 | ATM (0.55) | ATMDRD2DRD4OPRM1DRD3 | |
| SCHEMBL651852 | 0.77 | ATM (0.55) | ATMDRD2DRD4OPRM1DRD3 | |
| SCHEMBL10796236 | 0.77 | ATM (0.55) | ATMDRD2DRD4OPRM1DRD3 | |
| SCHEMBL2066381 | 0.77 | ATM (0.55) | ATMDRD2DRD4OPRM1DRD3 | |
| SCHEMBL1343715 | 0.76 | ATM (0.81) | ATMDRD2DRD4OPRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6759503-B2 | CYANOETHYLATED TOLUENEDIAMINES (CNTDAS), PROCESSES FOR SYNTHESIZING THEM, AND COMPOSITIONS CONTAINING THEM THE CNTDAS ARE PARTICULARLY SUITABLE FOR USE AS LATENT CURING AGENTS FOR EPOXY RESINS. | AIR PRODUCTS AND CHEMICALS, INC. | 2004-07-06 | — | — | US | disclosed |
| US-20030144540-A1 | N-cyanoethylated ortho and meta toluenediamine compositions and process for making them | STARNER WILLIAM EDWARD (US) | 2003-07-31 | — | — | US | disclosed |
| US-6593487-B1 | Latent curing agents for epoxy resins | AIR PRODUCTS AND CHEMICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1321459-A2 | N-Cyanoethylated ortho and meta toluenediamine compositions and process for making them | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-1321453-A2 | N-(Aminopropyl)-toluenediamines and their use as epoxy curing agents | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6441238-B1 | USING N-AMINOPROPYLTOLUENEDIAMINE | AIR PRODUCTS AND CHEMICALS, INC. | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144540-A1 | N-cyanoethylated ortho and meta toluenediamine compositions and process for making them | DNMT1, PNMT, TET1 | ATM 807/4885DRD2 113/4885DRD4 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.